Satellos Receives $1 Million Investment from Parent Project Muscular Dystrophy

Ontario Industry Updates
Written By Maura Campbell
Satellos-bioscience.png

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced a $1 million programmatic investment in Satellos Bioscience to support the development of a new regenerative medicine for the therapeutic treatment of Duchenne.

Maura Campbell
Previous

Globe and Mail features Providence Therapeutics in column, ‘Now we know why we need a vaccine industry in Canada'
Next

Flosonics receives funding to hire software developers